Alastair Goss
Med J Aust 2022; 217 (5): . || doi: 10.5694/mja2.51681
Published online: 5 September 2022

To the Editor: Khatri’s and Stuckey’s 1 article, Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk , sums up the authors’ knowledge and experience of medication‐related osteonecrosis of the jaws (MRONJ) in the latter part of the title. They quote the risk of MRONJ as being very low and equal for denosumab and oral bisphosphonates. This is incorrect. The risk of MRONJ is 0.3%. 2 In our study we found the risk following extractions at 1.8%. 3 The recent 2022 update of the position paper on MRONJ 4 found that the risk with denosumab is an order of magnitude higher than for bisphosphonates.

  • Alastair Goss

  • University of Adelaide, Adelaide, SA

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.
365电竞数据今日 企鹅电竞app登录网址(企鹅电竞选手下注) 电竞赚钱直播手机版网站 电竞赚钱战队数据app 英雄联盟竞猜比分入口 TT电竞比赛表